Medtronic (NYSE:MDT) today touted five-year data for its In.Pact Admiral drug-coated balloon, highlighting the durability and efficacy of its device in people with peripheral artery disease in the superficial femoral and popliteal arteries.
The company presented five-year results from its pivotal In.Pact SFA trial at the 2018 Vascular Interventional Advances conference.
Get the full story at our sister site, Drug Delivery Business News.